integrin

α2β1 Integrin Ligand Peptide acetate (α2β1 Integrin Ligand Peptide acetate (134580-64-6)) is a potential antagonist of α2β1 integrin receptor. α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells.

LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.

GRGDSP acetate(91037-75-1 free base) is a synthetic linear RGD peptide and is an integrin inhibitor.

Arg-Gly-Asp-Ser acetate is an integrin binding sequence that directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1. Arg-Gly-Asp-Ser acetate inhibits integrin receptor function.

Gly-Arg-Gly-Asp-Ser (GRGDS) acetate is a cell binding protein domain derived from the cell-binding region of fibronectin.

P11 acetate is an integrin αvβ3-vitronectin interaction antagonist(IC50 = 2.74 nM).

Hexapeptide-10 Acetate (Hexapeptide-10 Acetate) is a synthetic peptide. It increases the synthesis of laminin V and α6-integrin to promote cell binding, with extraordinary visible skin restructuring and firming abilities.

Arg-Gly-Asp TFA (99896-85-2(free base)) (RGD Trifluoroacetate) is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

Cilengitide (EMD 121974) is a potent integrin inhibitor for the αvβ3 5 receptor (IC50: 4.1 79 nM, in cell-free assays) with approximately 10-fold selectivity against gpIIbIIIa.

Arginine-glycine-aspartic acid

H-Gly-Arg-Gly-Asp-Asn-Pro-OH (GRGDNP) is a integrin-ligand interactions inhibitor.

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Cyclo(-RGDfK) (Cyclo (-RGDfK)) is an effective and specific αvβ3 integrin inhibitor.

Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

BIO-1211 is a more potent inhibitor of α4β1 (VLA-4, IC50 = 4 nM) over α4β7(IC50 = 2 μM).

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand extensively used for research, therapy, and diagnosis of neoangiogenesis. It also serves as a negative control for cyclo(-RGDfK-), the RGD peptide, which modulates cell adhesion and is recognized by several integrin family members.

iRGD peptide (c(CRGDKGPDC)) is a 9-amino acid cyclic peptide (sequence: CRGDKGPDC) and a molecular mimicry agent that was originally identified in an in vivo screening of phage display libraries in tumor-bearing mice.

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide and synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin on Caco-2 cells [1].

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro, also known as FITC-linked GRGDSP, is a fluorescent peptide with integrin inhibitory properties, which impedes tumor cell adherence to endothelial blood vessel cells, potentially restricting metastasis [1].

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.

VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activates FAK [1].

REDV TFA, the minimal active sequence of the CS5 site in the alternatively spliced type III connecting segment (IIICS) of fibronectin, mediates adhesion to the IIICS region of plasma fibronectin through binding with the integrin alpha 4 beta 1 (α4β1). It is utilized in cell adhesion research [1].

mP6 (Myr-FEEERA-OH), a myristoylated peptide, selectively inhibits Gα 13's interaction with integrin β 3 while preserving talin-dependent integrin function. Additionally, mP6 impedes the GTPase activity of Rac1, Rap1, and Rab7, effectively reducing the infection of CHO-A24 cells [1].

Anti-Mouse IL-1a Antibody is an IgG1 subtype inhibitor specific to mouse IL-1a, derived from the [Armenian Hamster].

cRGDfK-thioacetyl ester, a bioactive polypeptide, exhibits selective affinity for integrins and can modify near-infrared (NIR) fluorescent probes for targeted cancer imaging [1] [2].

Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective antagonist of the RGD peptide, with potential applications in pulmonary arterial hypertension research [1].

Integrin Signaling Inhibitor mP13 is a compound that impedes both inside-out and outside-in integrin-mediated signaling processes, such as fibrinogen binding, platelet adhesion, and clot retraction [1].

Integrin Binding Peptide, derived from fibronectin, holds the potential as an essential component for preparing PEG hydrogels.

α2β1 Integrin Ligand Peptide TFA interacts with integrin receptors on the cell membrane, mediating extracellular signaling and potentially acting as an antagonist of the collagen receptor.

The Asp-Gly-Glu-Ala (DGEA) amino acid domain of type I collagen interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.

GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.

Cyclo(-RGDfC)acetate is an integrin avb3-affine polypeptide, a circular RGDfc sequence.

Cyclo(-RGDyC)acetate is an integrin avb3-affine polypeptide, a circular RGDyc sequence. 

Arg-Gly-Asp-Ser is an integrin-binding sequence that inhibits integrin receptor function, thereby decreasing systemic inflammation by inhibiting collagen-triggered activation of leukocytes and attenuating the expression of inflammatory cytokines, MMP-9, and iNOS.

Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3)

REDV is a minimal active sequence found in the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin, critical for mediating adhesion to the IIICS region of plasma fibronectin through binding with integrin alpha 4 beta 1 (α4β1). It is utilized in cell adhesion research [1].

Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function.

Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide that regulates the functions of multiple integrin isoforms.

GRGDSPK (EMD 56574) is an inhibitory peptide for RGD-mediated adhesion between integrin and extracellular matrix molecules.

Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10), a decapeptide with a cyclic RGD active sequence, functions as an Integrin αIIbβ3 antagonist, effectively inhibiting platelet adhesion and proMMP-13 adhesion [1].

GRGDSP (TFA) is an integrin inhibitor.

Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor with antitumor properties, used in acute myeloid leukemia research [1].

Maraciclatide is a radiopharmaceutical targeting αvβ3 integrin.

A20FMDV2, a peptide derived from the α-helical RGD cell-interacting domain of the VP1 capsid protein of foot-and-mouth disease virus (FMDV) serotype O, targets and binds αVβ6 integrin. It effectively disrupts αVβ6 integrin-mediated cell adhesion in H357 tongue squamous cell carcinoma cells that exhibit human αVβ6, with an inhibitory concentration (IC50) of 1.2 µM. Additionally, when labeled with 111indium-DTPA, A20FMDV2 (20 MBq) specifically attaches to αVβ6 integrin in a breast cancer mouse xenograft model using MCF10CA1a cells, facilitating targeted radiation imaging analysis.

Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) is used as a soluble integrin-blocking RGD-based peptide.

GRGDSPK TFA (EMD 56574 TFA) is a peptide containing the Arg-Gly-Asp (RGD) sequence, serving as a competitive and reversible inhibitor of integrin-fibronectin binding. This compound is utilized in research to elucidate integrins' involvement in bone formation and resorption [1] [2].

HSDVHK-NH2 TFA acts as an antagonist to the αvβ3-vitronectin integrin interaction, displaying an inhibitory concentration (IC 50) of 1.74 pg/mL (2.414 pM) [1] [2].